CJC-1295 (No DAC)

GHRH (1-29) analogue · 29-residue peptide

Identifier graph

Cross-references to canonical chemistry knowledge graphs. Each binding is the same identity used in PubMed-indexed literature.

CAS Registry Number
863288-34-0 · CAS Common Chemistry
InChIKey
XOZMWINMZMMOBR-HRDSVTNWSA-N
PubChem CID
CID 56841945
Wikidata
Q5012018
ChEMBL
CHEMBL5927611
Molecular formula
C152H252N44O42
Molecular weight
3367.97 g/mol
IUPAC name
(3S)-4-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-4-oxobutanoic acid

What is CJC-1295 (No DAC)?

CJC-1295 (No DAC) — also called Modified GRF (1-29) or Mod-GRF(1-29) — is a 29-residue synthetic analogue of the N-terminal fragment of growth-hormone-releasing hormone (GHRH). It incorporates four substitutions that protect the peptide from rapid proteolytic cleavage by dipeptidyl peptidase-4 (DPP-IV) and other plasma proteases, while retaining full agonist activity at the GHRH receptor.

The "No DAC" designation distinguishes this variant from CJC-1295 with DAC, which carries an additional drug affinity complex (DAC) — a maleimidopropionic acid moiety that irreversibly binds plasma albumin and dramatically extends the peptide's half-life. The No-DAC form retains GHRH receptor selectivity with a more physiological half-life of approximately 30 minutes.

CAS 863288-34-0, molecular formula C₁₅₂H₂₅₂N₄₄O₄₂, molecular weight 3367.97 g/mol.

Mechanism of action

CJC-1295 (No DAC) binds the growth-hormone-releasing-hormone receptor (GHRHR) on pituitary somatotrophs and stimulates pulsatile GH secretion. The four amino-acid substitutions (D-Ala²·²Aib¹⁵·²Gln²⁵·²Leu²⁷) confer protection against DPP-IV cleavage at the N-terminus and other endogenous proteases.

The compound is commonly investigated alongside ghrelin mimetics (Ipamorelin, GHRP-2) because GHRH-receptor activation and GHSR-1a activation are mechanistically synergistic — the two pathways produce greater pulsatile GH release in combination than either pathway alone.

Research context

Investigated in preclinical models of GH-deficient states, adiposity and lean-mass partitioning, and bone-density changes. The 30-minute half-life makes it a common choice for protocols that require GH-pulse modelling rather than the sustained- release profile of the DAC variant.

Analytical specifications

Every batch of CJC-1295 (No DAC) supplied by NMChem is characterised by reversed-phase HPLC for purity determination and by mass spectrometry for identity confirmation. Certificate of Analysis (COA) documents are issued per batch and made available on request.

Identity is confirmed by electrospray-ionisation mass spectrometry (ESI-MS); the observed mass falls within ±2 Da of the theoretical monoisotopic mass calculated from the residue sequence. Purity is determined by reversed-phase HPLC on a C18 column with a trifluoroacetic-acid-modified water/acetonitrile gradient and reported as the area-under-curve percentage of the main peak at 214 nm. NMChem specification is ≥99% main peak. Material ships as lyophilised powder and must be reconstituted in sterile water or bacteriostatic water immediately before use.

Browse the COA database

UK regulatory status

Supplied as a research-grade reference standard for laboratory use only. Not a licensed medicinal product in the United Kingdom and not approved by the MHRA for human or veterinary administration. Sale is restricted to researchers, institutions and laboratory professionals; the compound must be retained within research premises. End-user compliance with the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971 (where applicable) and local institutional biosafety policy is the responsibility of the buyer.

Related compounds

Other research compounds in adjacent mechanism classes or commonly used alongside CJC-1295 (No DAC).

  • CJC-1295 (with DAC)
    GHRH analogue with albumin-binding DAC · 30-residue peptide
  • Ipamorelin
    Pentapeptide · GHSR-1a agonist (ghrelin mimetic)
  • Tesamorelin
    GHRH(1-44) analogue with N-terminal fatty acid · 44-residue peptide
  • GHRP-2
    Pentapeptide · GHSR-1a agonist (ghrelin mimetic)

Frequently asked questions about CJC-1295 (No DAC)

What does 'No DAC' mean in CJC-1295 (No DAC)?
DAC stands for Drug Affinity Complex — a maleimidopropionic-acid moiety that irreversibly attaches to plasma albumin and dramatically extends the peptide's plasma half-life (to ~6-8 days for the DAC variant, compared to ~30 minutes for the No-DAC variant). 'No DAC' is the shorter-half-life form, equivalent to Modified GRF (1-29).
Is CJC-1295 (No DAC) the same as Modified GRF (1-29)?
Functionally yes — both refer to the same 29-residue GHRH analogue with the four protease-resistance substitutions and no albumin-binding tether. 'Modified GRF (1-29)' and 'CJC-1295 (No DAC)' are interchangeable names in the research literature.
Why is CJC-1295 (No DAC) commonly combined with Ipamorelin?
GHRH-receptor activation (CJC-1295) and GHSR-1a activation (Ipamorelin) are mechanistically synergistic. Co-stimulation produces greater pulsatile growth-hormone release than either pathway alone in published preclinical models. NMChem supplies a 5 mg + 5 mg blend specifically for protocols that require both activities.

Get research-grade CJC-1295 (No DAC) from NMChem

UK supplier · HPLC and MS verified · Per-batch Certificate of Analysis · Tracked Royal Mail dispatch.

View product specifications →